SOPHiA GENETICS SA (SOPH) CSO trades 10,000 shares under 10b5-1 plan

Rhea-AI Filing Summary

SOPHiA GENETICS SA reports that Chief Scientific Officer Zhenyu Xu sold 10,000 Ordinary Shares on August 4, 2026 at a weighted average price of $6.9168 per share under a duly adopted Rule 10b5-1(c) trading plan, in trades priced between $6.90 and $6.95, leaving 600,887 shares held directly.

Insider Trade Summary 10b5-1

Net Seller: 10,000 shares

Net Sell 1 txn

Insider Xu Zhenyu

Role Chief Scientific Officer

Sold 10,000 shs ($69K)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares F1, F2	10,000	$6.9168	$69K

Holdings After Transaction: Ordinary Shares — 600,887 shares (Direct)

Footnotes (2)

1. F1. Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c).
2. F2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $6.90 to $6.95, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Key Figures

Shares sold: 10,000 shares Weighted average sale price: $6.9168 per share Sale price range: $6.90 to $6.95 per share +2 more

5 metrics

Shares sold 10,000 shares Ordinary Shares sold on 2026-08-04 by Chief Scientific Officer Zhenyu Xu

Weighted average sale price $6.9168 per share Weighted average price reported for the non-derivative sale

Sale price range $6.90 to $6.95 per share Range of prices for multiple sale transactions comprising the reported trade

Shares held after sale 600,887 shares Ordinary Shares directly owned by Zhenyu Xu following the transaction

Net shares sold in filing 10,000 shares Net change in non-derivative share holdings across all reported transactions

Key Terms

Rule 10b5-1(c), weighted average price, Ordinary Shares

3 terms

Rule 10b5-1(c) financial

"Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c)."

Rule 10b5-1(c) is an SEC guideline that lets company insiders set up a written, pre-planned schedule to buy or sell their company stock when they are not in possession of material, nonpublic information. For investors, it matters because such plans can reduce the appearance of insider trading by separating decisions from inside knowledge—like putting your trades on autopilot—while also requiring scrutiny since pre-planned trades can still affect market confidence and share value.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Ordinary Shares financial

"Security title reported for the transaction is Ordinary Shares."

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/05/2026 - 04:14 PM Accepted by SEC EDGAR 08/05/2026 - 04:13 PM Learn about SEC filing dates

FAQ

What insider transaction did SOPHiA GENETICS (SOPH) report in this Form 4?

SOPHiA GENETICS reported that Chief Scientific Officer Zhenyu Xu sold 10,000 Ordinary Shares on August 4, 2026. The non-derivative sale used a weighted average price of $6.9168 per share and was executed under a duly adopted Rule 10b5-1(c) trading plan.

At what prices did Zhenyu Xu sell SOPHiA GENETICS (SOPH) shares?

The reported Form 4 lists a weighted average sale price of $6.9168 per share. A footnote explains the shares were sold in multiple transactions at prices ranging from $6.90 to $6.95 per share, and detailed trade data is available on written request.

How many SOPHiA GENETICS (SOPH) shares does Zhenyu Xu hold after this sale?

Following the reported sale, Chief Scientific Officer Zhenyu Xu directly holds 600,887 Ordinary Shares of SOPHiA GENETICS SA. This post-transaction holding reflects the position after disposing of 10,000 shares in the August 4, 2026 non-derivative sale transaction.

Was the SOPHiA GENETICS (SOPH) insider sale under a Rule 10b5-1 plan?

Yes. The Form 4 indicates the transaction was made pursuant to a duly adopted trading plan under Rule 10b5-1(c). The document-level 10b5-1 checkbox is marked, and a footnote reiterates that the sale followed this pre-arranged trading plan framework.

What type of security did Zhenyu Xu trade in SOPHiA GENETICS (SOPH)?

The transaction involved Ordinary Shares of SOPHiA GENETICS SA, reported as a non-derivative security. The Form 4 shows no accompanying derivative transactions, and the derivative holdings summary is empty, so only common equity was affected in this particular filing.

Did the SOPHiA GENETICS (SOPH) filing indicate any derivative exercises by Zhenyu Xu?

No derivative exercises are reported in this Form 4. The transaction summary shows 0 derivative transactions and 0 exercise shares, and the derivative holdings section is empty, indicating only a sale of Ordinary Shares was disclosed in this filing.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Xu Zhenyu

(Last) (First) (Middle)

C/O SOPHIA GENETICS SA

LA PIECE 12

(Street)

ROLLE 1180

(City) (State) (Zip)

SWITZERLAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
SOPHiA GENETICS SA [ SOPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	08/04/2026		S		10,000(1)	D	$6.9168(2)	600,887	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c).

2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $6.90 to $6.95, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

	/s/ Elimara Brunetto as Attorney-in-fact for Zhenyu Xu	08/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)